Secure the Headset
Place the light-occluding SmartVertigo™ headset on the patient. Fits comfortably; ready in seconds.
✓ No Infrared Cameras
The First True Smart Mobile Video Oculography
Seeing nystagmus in the palm of your hand.
Vertigo used to be complicated. With SmartVertigo™, it doesn’t have to be.
The first clinical-grade, point-of-care vestibular wearable, with AI-guided assistance for nystagmus classification. We bring the vestibular lab to wherever the patient is — captured, classified and reviewable on the spot.
Smartphone + Headset + SmartVertigo™ App = SmartVertigo™
37 million Americans suffer from dizziness every year — and 4.8 million land in the ER, where most leave without a clear diagnosis.1
FDA 510(k) Cleared — K260566Rx Only3+ Years Field Tested4K+ Patient EncountersDeveloped with Florida Atlantic UniversityAI-Guided Nystagmus Classification
How It Works
Three steps. Deploy Cyclops Mode.
Familiar protocols.
Position the Patient
Execute the standard positional tests — Dix-Hallpike, supine roll. Familiar protocols, no retraining required.
✓ No Dedicated Workstation
Capture & Analyse
The system records real-time, high-fidelity eye movements via video. Review at speed, in slow motion, or frame by frame — instantly.
✓ No Cables
Straight Head HangDix-HallpikeSupine Roll
Why SmartVertigo?
A mini vestibular lab in the palm of your hand.
Cost
A fraction of legacy VNG
Traditional infrared VNG goggles run $3,000 to $50,000+. SmartVertigo™ uses the device already in your pocket, paired with a proprietary headset and intelligent app.
POC
Point Of Care
Fits in a small light carry case. Evaluation and treatment anywhere, anytime.
Rapid
Classification
Streamlined workflows. From patient presentation to documented BPPV classification in minutes, for the treating clinician to review.
Specialist
Specialist-level classification
Capture horizontal, vertical, and torsional nystagmus in high resolution. Replay at regular or slow speed to confirm subtle findings.
4K+
Patient encounters field-tested
Over three years of real-world clinical use. Consistent and reproducible in daily use.
<60s
AI-guided assistance for nystagmus classification
From capture to canal-specific classification at point of care. All diagnostic and therapeutic decisions remain with the treating clinician.
Clinician-supervised · Rx Only
SmartVertigo™ AI-Guided Assistance
Are you ready for AI copilot to assist you?
Classify → Suggest location → Present maneuver options
Step 1 — Classify
Identify the pattern
Identifies the nystagmus pattern — upbeat torsional, left horizontal, and others — using a machine-learning model trained on tens of thousands of clinical data points with Florida Atlantic University.
Step 2 — Localize
Suggest the likely canal
Suggests the likely affected otolith location from the classified nystagmus pattern, for the clinician to consider.
Step 3 — Inform
Present the maneuver options
Presents the repositioning maneuvers associated with that classification — Epley, Gufoni, or Reverse Semont — for the treating clinician to select from.
Clinical decision-making
1. Diagnostic classifications. All diagnostic classifications are made by the treating clinician. SmartVertigo™ provides AI-guided assistance for nystagmus classification, based on the classification of vestibular signs and examination techniques set out in the Bárány Society consensus document.1
2. Therapeutic decisions. All therapeutic decisions are made by the treating clinician. SmartVertigo™ provides an algorithmic formula that may be used to assist the treating clinician in selecting the optimal therapeutic maneuver. This formula is based on industry-standard maneuver selection and on the diagnostic classifications described in section 1.
All decisions, whether diagnostic or therapeutic, remain the ultimate responsibility of the treating clinician.
1 Eggers SDZ, Bisdorff A, von Brevern M, Zee DS, Kim J-S, Pérez-Fernández N, Welgampola MS, Della Santina CC, Newman-Toker DE. Classification of vestibular signs and examination techniques: Nystagmus and nystagmus-like movements. Consensus document of the Committee for the International Classification of Vestibular Disorders of the Bárány Society. Journal of Vestibular Research. 2019;29(2–3):57–87.
The Value Proposition
Close the vestibular assessment gap.
Easily reproducible 3-step process.
SmartVertigo™ empowers every clinician — not just the specialist — to objectively capture, classify and document nystagmus with confidence. By combining high-fidelity nystagmus capture with intuitive clinical guidance, we replace the complicated, bulky, expensive vestibular lab with one portable self-contained system. Best of all, you can learn to use it in minutes.
Point-of-Care Recording
Close-up eye-movement video, captured during positional testing.
Recorded through the SmartVertigo™ headset for clinician review, playback, and documentation.
Built for the Clinicians Who See Vertigo First
Built for the clinicians who see vertigo first.
Whether you’re managing a busy emergency department, running a vestibular PT practice, or evaluating a neurology consultation in the hospital, SmartVertigo™ delivers the objective evidence efficiently.
See What a CT Can’t.
Dizziness is vague. SmartVertigo™ isn’t. 35% of ED dizziness patients receive brain imaging⁵ — and 93.1% of those scans come back unremarkable.⁶ Bedside nystagmus recording turns medicine’s most ambiguous presentation into objective, reproducible, documented data. Results within minutes. Once BPPV is confirmed, SmartVertigo™ suggests the likely repositioning maneuver — so you’re not relying on memory alone.
Read more →
BPPV, Simplified.
BPPV demands you remember positions, nystagmus patterns, and canal classification. SmartVertigo™ handles all of it — guiding you through every step. Confirms the canal. Walks you through the treatment maneuver. No guessing, no reference chart.
Read more →
Central vs. Peripheral — Decided at the Bedside.
In stroke evaluation, speed is everything — and dizziness remains one of the hardest presentations to call when deciding on administering thrombolytics. SmartVertigo™ puts objective, documented nystagmus recording in your hands at the bedside. Faster decisions. A defensible record every time.
Read more →In-Home Care
The Mobile Concierge Practice Advantage.
This mini vestibular lab fits in a small, light portable case — so it goes with you. For the mobile PT, or the concierge clinician performing an in-home visit, SmartVertigo™ unlocks a category of care that was previously impossible outside a hospital or specialty clinic.
The entire system — headset, smartphone interface, and proprietary app — fits into a single durable travel case. One operator. No infrastructure required at the point of delivery.
- Frail & elderly patients: eliminate transport risk and bring the test to them.
- EMR-ready documentation: instant PDF report sent directly into the patient’s chart from the field.
- SmartVertigo™ Field Kit — Single-Operator · No Setup · In-Home Ready.
The SmartVertigo™ Advantage
Beyond the assessment.
An assessment device is only as valuable as the workflow around it. SmartVertigo™ is built end-to-end to translate clinical observations into documentation, billing, longitudinal care, and patient engagement.
Slow-Motion Replay
Replay at variable speeds to confirm what the naked eye misses.
Longitudinal Tracking
A true clinical timeline. Every visit recorded and accessible on the VertigoDx portal — canal involvement, treatment response, and recurrence, all in one place.
Instant EMR-Ready PDF
Export comprehensive, formatted reports directly into the chart — no copying, no transcription, no missing documentation. Less time on charts. More time on patients.
Defensible Billing Evidence
Captured eye-movement sequences serve as objective data supporting applicable CPT vestibular function and repositioning codes — including evaluation codes 97161-3, re-evaluation codes 97164, neuromuscular codes 97112, therapeutic activities 97530, and canalith repositioning 95992.*
Patient Education Tool
Let patients see what you see. Showing real nystagmus footage turns a confusing diagnosis into something patients can understand, follow, and trust.
Medicolegal Documentation
A contemporaneous, reproducible record that objectively corroborates every clinical decision.
Everything the infrared goggle does, plus five things it can’t — at a fraction of the cost.
| Feature comparison | Frenzel Goggles | Infrared Goggles | SmartVertigo™ |
|---|---|---|---|
| Affordable | ✓ | ~ | ✓ |
| Fully portable & wireless | ✓ | ✗ | ✓ |
| True point-of-care | ✓ | ✗ | ✓ Exclusive |
| Clear magnification eye capture | ✗ | ✗ | ✓ Exclusive |
| Unlimited replays | ✗ | ✓ | ✓ |
| Track patient progress with side-by-side videos | ✗ | ✗ | ✓ Exclusive |
| AI-guided nystagmus classification | ✗ | ✗ | ✓ Exclusive |
| Seamless EMR integration | ✗ | ✗ | ✓ Exclusive |
| Reproducible record | ✗ | ~ | ✓ |
✓ Available · ~ Partial / limited · ✗ Not available · Exclusive = SmartVertigo™ only. *CPT coding and reimbursement are the responsibility of the treating provider and are not guaranteed by VertigoDx.
The Cost of the Status Quo
Vertigo is expensive to get wrong.
$2BSpent every year in the U.S. on diagnosing BPPV alone.²
$2,000Average cost to reach a single BPPV diagnosis under the current model.²
65%+Of BPPV patients undergo potentially unnecessary testing or treatment.²
Research & Validation
Built on clinical evidence, not marketing claims.
SmartVertigo™ is currently being validated in an IRB clinical study with FAU.
4K+Patient encounters across more than three years of field-tested clinical practice.
FAUAI algorithm developed in collaboration with Florida Atlantic University.
510(k)Cleared under K260566, 30 July 2026. Protected by a filed provisional patent.
Leadership
The team behind the platform.
Dr. Paul Louis
Chief Executive OfficerA graduate of the University of Miami Miller School of Medicine, Dr. Louis is a board-trained Emergency Medicine physician with more than 30 years of clinical practice. As co-inventor and commercializer of SafetyNeb™, he demonstrated an ability to bring a specialized medical device from initial design to national distribution within six months during the COVID-19 pandemic, achieving more than 10,000 units sold in the first two quarters and adoption across 20 states. Dr. Louis provides SmartVertigo™ with a trifecta of clinical expertise, quality management, and go-to-market execution.
Trevor Meyerowitz, PT
Chief Medical OfficerWith 36 years of clinical practice and more than 15,000 successful vestibular treatments, Trevor Meyerowitz is a subject-matter authority on the diagnosis and management of vertigo. The SmartVertigo™ System emerged directly from his clinical practice, where he identified persistent diagnostic limitations and responded by engineering a platform that translates complex nystagmus patterns into actionable, canal-specific clinical data. His proprietary dataset, accumulated over thousands of treatment encounters, forms the foundation of the system’s machine-learning model and underpins its diagnostic concordance with specialist review.
Stephen Meyerowitz
Chief Technical OfficerStephen Meyerowitz is a veteran technologist with more than 32 years of experience in medical-grade hardware and software integration. Holding a B.Com Honours degree in Information Technology, he has a documented record of building and scaling globally distributed medical systems. His technical leadership is responsible for the SmartVertigo™ architecture — bridging machine-learning analytics with a user-centric clinical interface — and he oversees the product’s technical roadmap to ensure platform robustness, security, and scalability for global deployment.
Alan Keschner
Chief Financial OfficerA Mechanical Engineer with a Master’s degree in Industrial Administration, Alan Keschner brings more than 42 years of experience across high-growth startups and established corporate environments, with particular focus on mergers, acquisitions, and statutory compliance. He provides the financial stewardship and structural rigor necessary for venture-backed growth, overseeing the legal and financial frameworks that protect shareholder value while navigating the complexities of medical device commercialization.
KB
Kowshik Balasubramanian
AI SpecialistKowshik Balasubramanian is an AI innovator holding a Master’s in Information Technology Management from Florida Atlantic University, specializing in proprietary AI solutions. At VertigoDx, Kowshik served as the driving force behind the company’s AI strategy, taking the concept from idea to reality. His work produced a proprietary system capable of identifying vestibular dysfunction from patient videos in under a minute. He is currently expanding his expertise into the insurance and energy sectors.
Get in Touch
Bring the vestibular lab to your point of care.
Request a demo, ask a clinical question, or explore enterprise and federal licensing. Our team responds within one business day.
Patent & FDA Status
Patent Pending — Worldwide PCTFDA 510(k) Cleared — K260566 · Rx Only — Prescription Use
SmartVertigo™ is patent pending, including a worldwide PCT patent application and related provisional patent filings.
SmartVertigo™ is FDA 510(k) cleared under K260566, granted 30 July 2026. It is a prescription-use device intended for use by licensed healthcare professionals.
References
The evidence behind the numbers.
- Miulli MM, Kim HS. U.S. Emergency Department Visits for Dizziness and Vertigo From 2016 to 2022. Academic Emergency Medicine. 2026 Jan 13. doi:10.1111/acem.70214. — 4.8 million annual ER dizziness visits; 37 million Americans affected by dizziness annually.
- American Academy of Otolaryngology–Head and Neck Surgery Foundation. Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update). 2017. — 5.6 million annual U.S. dizziness clinic visits; 17–42% of vertigo patients diagnosed with BPPV; ~$2,000 average cost to diagnose BPPV; >65% of BPPV patients undergo potentially unnecessary testing or treatment.
- Palmeri R, Kumar A. Benign Paroxysmal Positional Vertigo. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated 2025 Nov. — dizziness accounts for over 3 million ED visits annually.
- Vestibular Disorders Association (VeDA). Benign Paroxysmal Positional Vertigo (BPPV). — BPPV lifetime prevalence of 2.4%; incidence 107 per 100,000 per year.
- Adams ME, Karaca-Mandic P, Marmor S. Use of Neuroimaging for Patients With Dizziness Who Present to Outpatient Clinics vs Emergency Departments in the US. JAMA Otolaryngol Head Neck Surg. 2022 May 1;148(5):465-473. doi:10.1001/jamaoto.2022.0329. — approximately 35% of ED patients with dizziness receive brain imaging.
- Masood A, Alkhaja O, Alsetrawi A, et al. The Diagnostic Value of Brain CT Scans in Evaluating Dizziness in the Emergency Department: A Retrospective Study. Cureus. 2024 Jan 18;16(1):e52483. doi:10.7759/cureus.52483. — 93.1% of brain CT scans ordered for ED dizziness presentations were unremarkable.